Centralised EU review speeds access to Lyme disease vaccine
The European Medicines Agency's evaluation of a breakthrough tick vaccine shows how collective regulatory approval delivers health innovations across all 27 member states at once.
By United States of Europe editorial team · How we write editorial
The European Medicines Agency has begun evaluating a breakthrough vaccine targeting Lyme disease. The treatment works by killing the bacteria directly inside the stomach of ticks, achieving a 74 percent efficacy rate in clinical trials.
Lyme disease is the main vector-borne infection in Europe. As changing climate patterns expand tick habitats, vector-borne illnesses pose a growing threat to public health across borders.
Sceptics of centralised regulation often argue that national agencies are better placed to judge local health needs and maintain direct oversight. National sovereignty over medical approvals can feel reassuring to local electorates.
Yet running 27 separate scientific evaluations for the same treatment creates unnecessary delays and duplicates expensive research. A single, rigorous assessment by the European Medicines Agency ensures high safety standards without geographic disparity.
When approval comes through one shared agency, citizens in every member state gain access to life-saving innovation at the exact same moment. Pooling scientific expertise in health regulation remains one of Europe's quietest successes.
Drafted with AI, edited by the editor.